Dialysis adequacy and health related quality of life in hemodialysis patients

被引:52
作者
Manns, BJ
Johnson, JA
Taub, K
Mortis, G
Ghali, WA
Donaldson, C
机构
[1] Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada
[2] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada
[3] Univ Calgary, Dept Econ, Calgary, AB T2N 1N4, Canada
[4] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
关键词
D O I
10.1097/00002480-200209000-00021
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Patients with end-stage renal disease have significant impairments in health related quality of life (HRQOL). The determinants of HRQOL, including the effect of dialysis adequacy, have not been well studied. This study was designed to investigate whether dialysis adequacy is associated with HRQOL in hemodialysis patients. A cross-sectional survey of 128 patients who had been on hemodialysis for more than 6 months was conducted. Baseline information on demographic factors and detailed clinical information was collected. Average Kt/V levels (for the 3 months preceding HRQOL assessment) were determined. HRQOL was assessed with the Kidney Disease Quality of Life Short Form, the Short Form-36 (SF-36), and the EuroQol EQ-5D. Multiple linear regression was performed to control for differences in important baseline covariates. Patients with average Kt/V levels greater than or equal to 1.3 had better HRQOL as measured by significantly higher scores (p < 0.05) in 4 of 11 kidney disease targeted domains, 6 of 8 SF-36 domains, and on the EQ-5D visual analog scale and index score. Using multiple linear regression to control for important covariates, the adjusted EQ-5D index score was higher by 0.036 (95% confidence intervals 0.015, 0.057) for each 0.1 increment in Kt/V, which is both statistically and clinically significant. Dialysis adequacy was significantly associated with HRQOL in hemodialysis patients. Controlled studies that examine the effect of increasing Kt/V on HRQOL are needed.
引用
收藏
页码:565 / 569
页数:5
相关论文
共 32 条
[1]   A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients [J].
Beddhu, S ;
Bruns, FJ ;
Saul, M ;
Seddon, P ;
Zeidel, ML .
AMERICAN JOURNAL OF MEDICINE, 2000, 108 (08) :609-613
[2]  
Brissenden J. E., 1998, Journal of the American Society of Nephrology, V9, p168A
[3]  
*CAN COORD OFF HLT, 1997, GUID EC EV PHARM
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]  
CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14
[6]   Economic evaluation of end stage renal disease treatment [J].
de Wit, GA ;
Ramsteijn, PG ;
de Charro, FT .
HEALTH POLICY, 1998, 44 (03) :215-232
[8]   Modeling valuations for EuroQol health states [J].
Dolan, P .
MEDICAL CARE, 1997, 35 (11) :1095-1108
[9]  
Drummond M., 2015, METHODS EC EVALUATIO, V4
[10]  
GARRED L, 1992, BLOOD PURIFICAT, V10, pA90